Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NBSE

NeuBase Therapeutics (NBSE) Stock Price, News & Analysis

NeuBase Therapeutics logo

About NeuBase Therapeutics Stock (NASDAQ:NBSE)

Key Stats

Today's Range
$0.38
$0.38
50-Day Range
$0.38
$0.38
52-Week Range
$0.36
$4.80
Volume
N/A
Average Volume
N/A
Market Capitalization
$1.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive NBSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NBSE Stock News Headlines

Greenlight Capital Q3 2024 Letter
The 7 Warning Signals Flashing Red Right Now
A free report revealing the 7 key indicators that have predicted every major economic collapse since 1929. Right now, all seven are flashing red simultaneously for the first time since 2007. These aren't the signals you'll see on CNBC.tc pixel
See More Headlines

NBSE Stock Analysis - Frequently Asked Questions

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) released its quarterly earnings results on Thursday, December, 23rd. The company reported ($4.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($4.60) by $0.40.

NeuBase Therapeutics shares reverse split on the morning of Thursday, June 15th 2023.The 1-20 reverse split was announced on Thursday, June 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuBase Therapeutics investors own include Pfizer (PFE), Energy Transfer (ET), Sio Gene Therapies (SIOX), Avino Silver & Gold Mines (ASM), Actinium Pharmaceuticals (ATNM), Cytokinetics (cytk) and Enbridge (enb).

Company Calendar

Last Earnings
12/23/2021
Today
10/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NBSE
CIK
1173281
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
3,750,000
Free Float
3,456,000
Market Cap
$1.43 million
Optionable
Not Optionable
Beta
N/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:NBSE) was last updated on 10/13/2025 by MarketBeat.com Staff
From Our Partners